Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Simulations Plus Inc (NASDAQ:SLP) stock tanked after the company lowered its fiscal 2025 sales outlook. The company expects third-quarter sales of $19 million-$20 million, much below the consensus of ...

Simulations Plus Inc. (NASDAQ: SLP) shares climbed on Tuesday after the company reported better-than-expected fourth-quarter 2025 earnings and reaffirmed annual guidance. • SLP is among today’s top ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...